Lumena Pharmaceuticals is testing LUM001 in children with Alagille syndrome (ALGS). The first patient has been dosed in the IMAGO Phase II study being conducted in the UK, and enrollment of pediatric patients is expected to begin later this year in the ITCH Phase II study in the U.S. The IMAGO study is a 13 week placebo-controlled study to evaluate the safety and efficacy of LUM001 in children with ALGS. The UK-based study will enroll children, two years of age and older, with ALGS. ALGS is a r...